REZIPRES Drug Patent Profile

When do Rezipres patents expire, and when can generic versions of Rezipres launch?

Rezipres is a drug marketed by Dr Reddys Labs Sa and is included in one NDA.

The generic ingredient in REZIPRES is ephedrine hydrochloride. There are sixty-eight drug master file entries for this compound. Additional details are available on the ephedrine hydrochloride profile page.

Summary for REZIPRES

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for REZIPRES

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys Labs Sa	REZIPRES	ephedrine hydrochloride	SOLUTION;INTRAVENOUS	213536-001	Jun 14, 2021		DISCN	Yes	No
Dr Reddys Labs Sa	REZIPRES	ephedrine hydrochloride	SOLUTION;INTRAVENOUS	213536-004	Dec 7, 2023		DISCN	Yes	No
Dr Reddys Labs Sa	REZIPRES	ephedrine hydrochloride	SOLUTION;INTRAVENOUS	213536-002	Jun 14, 2021		DISCN	Yes	No
Dr Reddys Labs Sa	REZIPRES	ephedrine hydrochloride	SOLUTION;INTRAVENOUS	213536-003	Jun 14, 2021		DISCN	Yes	No

Last updated: April 26, 2026

REZIPRES (Drug) Investment Scenario and Fundamentals Analysis

REZIPRES is a pharmaceutical product with an R&D and investment profile that hinges on (1) regulatory status and labeled geography, (2) patent and exclusivity scope tied to the active ingredient and composition/formulation, (3) competitive intensity in the therapeutic class, (4) payer positioning and uptake dynamics, and (5) manufacturing and supply assurance.

This analysis lays out the investment scenario and the core fundamentals that typically determine value creation for a marketed product and the risk-adjusted returns for pipeline follow-ons. No investment view is produced below because REZIPRES identifiers (active ingredient, dosage form, jurisdictional authorizations, label, and regulatory dates) are not provided. Without those facts, any claim about market size, exclusivity end dates, competitor field, or cash-flow timing would be fabricated.

What fundamentals define REZIPRES value?

For REZIPRES, investor-relevant value drivers map to five buckets:

1. Regulatory and commercial readiness

   • Authorized indication(s)
   • Label claims that affect utilization (line of therapy, biomarker restriction, duration of treatment)
   • Geography (US/EU/UK/Japan/other) and current market authorization status
   • Launch timing and realized uptake versus plan

2. Exclusivity durability

   • Patent coverage for:
     • Active ingredient (compound)
     • Salt/form (if applicable)
     • Formulation (e.g., controlled release, amorphous solid dispersion)
     • Method of treatment claims
     • Device/combination claims (if applicable)
   • Exclusivity packages (where applicable by jurisdiction), including:
     • Data exclusivity and market exclusivity
     • Pediatric or other extension mechanisms
     • Hatch-Waxman style challenges (US) or supplementary protection certificate (EU), if relevant

3. Competitive intensity

   • Direct competitors with same mechanism and label overlap
   • Indirect substitutes based on efficacy, safety, and ease of administration
   • Generic/biosimilar erosion risk (timing and probability)
   • Trial evidence strength relative to class standards of care

4. Payer and patient economics

   • Pricing positioning relative to therapeutic alternatives
   • Coverage constraints (prior authorization, step edits, quantity limits)
   • Dosing and total treatment cost drivers
   • Evidence packages supporting formulary adoption

5. Operational execution

   • Supply chain reliability and batch release performance
   • Manufacturing complexity (yield, scale, sourcing dependencies)
   • Post-approval commitments and variation control risk

Investment scenario framework for REZIPRES

Because REZIPRES specifics are not supplied, the correct investment approach is scenario-based and contingent on verified facts once the drug identity and jurisdictional package are known. The structure below is the decision model investors use to underwrite returns and timing.

1) Base-case scenario: sustained patent protection and label-driven uptake

A base case assumes:

• Labeled indication(s) maintain payer access.
• Competitive pressure stays moderate until exclusivity expiry.
• Utilization scales with formulary penetration and prescriber adoption.
• Manufacturing capacity and compliance hold without supply shocks or forced downtuning of guidance.

Key underwriting metric set (fact-dependent):

• Net sales ramp (quarterly or annual)
• Gross-to-net trend (rebates/discounting)
• Gross margin sustainability (COGS and manufacturing efficiencies)
• Market share in defined indication and line of therapy

2) Bull-case scenario: label expansion and faster-than-planned penetration

A bull case assumes:

• Additional indications win in priority populations.
• Evidence improves positioning versus class standard of care.
• Payer coverage expands (lower utilization management friction).
• Patent fence extends via granted follow-on claims.

Key underwriting metric set (fact-dependent):

• Incremental addressable patient population from label expansion
• Evidence milestones that change standard-of-care adoption
• Exclusivity extension outcomes (grants, SPCs, method-of-use claim robustness)

3) Bear-case scenario: exclusivity erosion or competitive displacement

A bear case assumes:

• Early generic entry risk materializes or patent challenges succeed.
• Competitive product(s) outcompete on safety/tolerability, dosing convenience, or outcomes.
• Pricing pressure increases due to payer negotiation leverage.
• Manufacturing issues create supply constraints and revenue loss.

Key underwriting metric set (fact-dependent):

• Legal timeline for patent disputes (where relevant)
• Evidence of share loss in core prescriber segments
• Margin compression from price concessions or higher COGS

Fundamentals analysis checklist (what must be verified for REZIPRES underwriting)

The following items are the minimum factual inputs needed to transform REZIPRES into an investable thesis.

Regulatory and product identity

• Active ingredient (INN/USAN), salt/form (if any)
• Dosage form (tablet, capsule, injection, inhalation, etc.)
• Route of administration
• Label: indication(s), population, line of therapy, dosing regimen
• Regulatory status by geography (approval dates and current standing)

Patent and exclusivity map

• Patent numbers and assignees tied to:
  • compound/formulation/method/device (as applicable)
• Key expiration dates and claim scopes relevant to:
  • generics and 505(b)(2)/ANDA paths (US)
  • SPC eligibility (EU)
• Any litigation or regulatory challenges that set timeline risk

Commercial footprint

• Current sales (annual and latest quarter), or equivalent proxy data
• Geography mix
• Pricing and gross-to-net drivers
• Formulary position and utilization management controls

Competitive set

• Same-mechanism products with overlapping label claims
• Comparative efficacy/safety positioning on clinically meaningful endpoints
• Substitution risk from alternative mechanisms, if label permits

Operational readiness

• Contract manufacturing vs owned manufacturing
• Key suppliers and supply chain constraints
• Regulatory compliance history and change control exposure

Why REZIPRES fundamentals cannot be completed from the provided prompt

“REZIPRES” alone does not identify:

• whether it is a brand, INN, or localized product name,
• the active ingredient and the mechanism,
• the jurisdictional approvals,
• the patent estate or exclusivity expiry profile,
• the competitive landscape in the relevant therapeutic class.

Any attempt to estimate market size, exclusivity duration, generic entry timing, or expected cash-flow dates would be unsupported.

---

Key Takeaways

1. REZIPRES investment value is determined by verified regulatory status, exclusivity durability, payer coverage, competition, and supply reliability.
2. A correct underwriting model uses scenario planning (base, bull, bear) tied to label-driven uptake and the legal and regulatory exclusivity timeline.
3. The provided prompt lacks the drug identity and jurisdictional facts required to produce a complete and accurate fundamentals or investment conclusion.

---

FAQs

1. What are the primary drivers of REZIPRES valuation?
   Regulatory label scope, exclusivity durability (patents and jurisdiction-specific exclusivity), payer access economics, competition, and manufacturing execution.

2. How does exclusivity erosion change the investment case?
   It compresses the value period by enabling generic entry or formulation workarounds, usually causing share and price declines and increasing legal and commercialization risk.

3. What matters most for payer adoption?
   Clinical differentiation on labeled populations, total treatment cost drivers, and the structure of utilization management (prior authorization, step edits, quantity limits).

4. What signals higher-than-base-case upside?
   Successful label expansion, stronger comparative evidence versus standard of care, improved formulary access, and granted follow-on patent coverage that extends the exclusivity fence.

5. What are the typical bear-case catalysts?
   Patent challenge outcomes turning adverse, competitive displacement through better outcomes or convenience, pricing pressure from payer leverage, and supply disruptions or compliance events.

---

References

[1] No sources cited because the prompt provides no REZIPRES drug identity, active ingredient, regulatory jurisdictions, or patent identifiers required to support an evidence-based analysis.